ProPhase Labs Company Top Insiders
PRPH Stock | USD 0.42 0.03 6.04% |
ProPhase Labs employs about 113 people. The company is managed by 10 executives with a total tenure of roughly 22 years, averaging almost 2.0 years of service per executive, having 11.3 employees per reported executive. Assessment of ProPhase Labs' management performance can provide insight into the firm performance.
Ted Karkus Chairman Chairman and CEO |
ProPhase |
ProPhase Labs Management Team Effectiveness
The company has return on total asset (ROA) of (0.2298) % which means that it has lost $0.2298 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5092) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -0.19. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.33. As of now, ProPhase Labs' Other Current Assets are decreasing as compared to previous years. The ProPhase Labs' current Intangible Assets is estimated to increase to about 14.9 M, while Total Current Assets are projected to decrease to under 27.5 M.The ProPhase Labs' current Net Income Applicable To Common Shares is estimated to increase to about 7.6 M, while Common Stock Shares Outstanding is projected to decrease to under 15.2 M.
ProPhase Labs Workforce Comparison
ProPhase Labs is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 8,247. ProPhase Labs claims roughly 113 in number of employees contributing just under 2% to equities under Health Care industry.
ProPhase Labs Profit Margins
The company has Profit Margin (PM) of (1.46) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.16) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $3.16.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.58 | 0.42 |
|
|
ProPhase Labs Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProPhase Labs insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProPhase Labs' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ProPhase Labs insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hirsch Warren over three months ago Acquisition by Hirsch Warren of 40000 shares of ProPhase Labs at 7.31 subject to Rule 16b-3 | ||
Louis Gleckel over six months ago Acquisition by Louis Gleckel of 40000 shares of ProPhase Labs at 7.31 subject to Rule 16b-3 | ||
Jason Barr over six months ago Acquisition by Jason Barr of 70000 shares of ProPhase Labs at 6.0 subject to Rule 16b-3 | ||
Ted Karkus over six months ago Disposition of 400000 shares by Ted Karkus of ProPhase Labs at 6.0 subject to Rule 16b-3 | ||
Leonard Braden Michael over a year ago Purchase by Leonard Braden Michael of 16900 shares of ProPhase Labs | ||
Morse Robert A Jr over a year ago Acquisition by Morse Robert A Jr of 50000 shares of ProPhase Labs subject to Rule 16b-3 | ||
Ted Karkus over a year ago Bona fide gift to Ted Karkus of 50000 shares of ProPhase Labs subject to Section 16 | ||
Ted Karkus over a year ago Bona fide gift to Ted Karkus of 100000 shares of ProPhase Labs subject to Section 16 |
ProPhase Labs Notable Stakeholders
A ProPhase Labs stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ProPhase Labs often face trade-offs trying to please all of them. ProPhase Labs' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ProPhase Labs' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ted Karkus | Chairman and CEO | Profile | |
Jason Karkus | President Diagnostics | Profile | |
Alice Lioi | EVP BioPharma | Profile | |
Billy White | Consultant | Profile | |
Lance Bisesar | Corporate Controller | Profile | |
Robert Morse | Principal Controller | Profile | |
Sergio Miralles | Executive Diagnostics | Profile | |
Kamal Obbad | Senior Genomics | Profile | |
Monica Brady | Principal Financial Officer & Principal Accounting Officer | Profile | |
Jed Latkin | Chief Department | Profile |
About ProPhase Labs Management Performance
The success or failure of an entity such as ProPhase Labs often depends on how effective the management is. ProPhase Labs management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ProPhase management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ProPhase management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.20) | (0.19) | |
Return On Capital Employed | (0.35) | (0.33) | |
Return On Assets | (0.18) | (0.16) | |
Return On Equity | (0.31) | (0.29) |
ProPhase Labs Workforce Analysis
Traditionally, organizations such as ProPhase Labs use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ProPhase Labs within its industry.ProPhase Labs Manpower Efficiency
Return on ProPhase Labs Manpower
Revenue Per Employee | 392.8K | |
Revenue Per Executive | 4.4M | |
Net Loss Per Employee | 148.5K | |
Net Loss Per Executive | 1.7M | |
Working Capital Per Employee | 236.5K | |
Working Capital Per Executive | 2.7M |
Complementary Tools for ProPhase Stock analysis
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |